Kilic Ebru Tarikci, Sayar Suleyman, Kahraman Resul, Ozdil Kamil
Department of Anesthesiology and Reanimation, Health Sciences University, Umraniye Training and Research Hospital, Istanbul, Turkey.
Department of Gastroenterology, Health Sciences University, Umraniye Training and Research Hospital, Istanbul, Turkey.
North Clin Istanb. 2019 Oct 24;6(4):321-326. doi: 10.14744/nci.2019.93763. eCollection 2019.
Current literature covers limited data on the safety of sedation in advanced endoscopic procedures in obese patients. The present study aims to evaluate the association between obesity and the frequency of sedation-related complications in patients who were undergoing advanced endoscopic procedures.
A retrospective chart analysis of 1172 consecutive patients, meeting the inclusion and exclusion criteria for this study and undergoing intravenous ketamine-propofol (ketofol) sedation for endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP) procedures were evaluated. The patients were classified into three groups according to their body mass index (BMI) (kg/m2). Group I comprised patients with a BMI between 25 and 30, group II with a BMI between 30 and 35, and group III with a BMI between 35-40. The sedation-related outcomes in the form of adverse events, and airway interventions were compared between the groups.
For analysis, out of the 1172 available records, 289 patients had a BMI between 35-40 and were predominantly male patients. The total adverse events were more common in obese patients, with apnea (in 5.5% patients in group I, 5.7% in group II, 22.8% in group III p<0.000), oxygen desaturation (in 7.7% patients in group I, 9.4% in group II, and 27.7% in group III p<0.000), and airway obstruction (in 4.9% patients in group I, 5.4% in group II, 22.8% in group III, p<0.000). Moreover, the obese patients more frequently required airway interventions, including airway placement, suctioning and bag-mask ventilation.
Higher BMI was associated with an increased frequency of sedation-related complications. However, we concluded that ketofol sedation regimen could be used safely in obese patients during advanced endoscopic procedures by skilled anesthesia providers.
目前的文献中关于肥胖患者进行高级内镜手术时镇静安全性的数据有限。本研究旨在评估肥胖与接受高级内镜手术患者镇静相关并发症发生频率之间的关联。
对1172例连续患者进行回顾性病历分析,这些患者符合本研究的纳入和排除标准,并接受了静脉注射氯胺酮-丙泊酚(氯胺酮复合丙泊酚)镇静下的内镜超声(EUS)和内镜逆行胰胆管造影(ERCP)手术。根据患者的体重指数(BMI)(kg/m²)将其分为三组。第一组为BMI在25至30之间的患者,第二组为BMI在30至35之间的患者,第三组为BMI在35至40之间的患者。比较各组之间以不良事件和气道干预形式出现的镇静相关结果。
为进行分析,在1172份可用记录中,有289例患者的BMI在35至40之间,且主要为男性患者。肥胖患者中总的不良事件更为常见,包括呼吸暂停(第一组患者中为5.5%,第二组为5.7%,第三组为22.8%,p<0.000)、氧饱和度下降(第一组患者中为7.7%,第二组为9.4%,第三组为27.7%,p<0.000)和气道阻塞(第一组患者中为4.9%,第二组为5.4%,第三组为22.8%,p<0.000)。此外,肥胖患者更频繁地需要气道干预,包括气道放置、吸痰和面罩通气。
较高的BMI与镇静相关并发症的发生频率增加有关。然而,我们得出结论,熟练的麻醉提供者在肥胖患者进行高级内镜手术期间可以安全地使用氯胺酮复合丙泊酚镇静方案。